News from viacyte, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jun 16, 2021, 08:00 ET ViaCyte to Present at the Raymond James 2021 Human Health Innovation Conference

ViaCyte, Inc., a clinical-stage regenerative medicine company focused on developing cell therapies that provide a functional cure for patients with...

Jun 09, 2021, 08:00 ET ViaCyte Announces Closing of $45 Million Financing to Advance Broadest Portfolio of Stem Cell-Derived Therapies for Type 1 Diabetes

ViaCyte, Inc., a clinical-stage regenerative medicine company, today announced the closing of a $45 million financing tranche that brings the total...

Jun 08, 2021, 07:00 ET ViaCyte Appoints Dr. Evert Kroon as Interim Chief Scientific Officer

ViaCyte, Inc., a clinical-stage regenerative medicine company focused on developing cell therapies that provide a functional cure for patients with...

Jun 01, 2021, 08:00 ET ViaCyte to Present Late-Breaking Data at the American Diabetes Association's 81st Scientific Sessions

ViaCyte, Inc., a clinical-stage regenerative medicine company focused on developing cell therapies that provide a functional cure for patients with...

May 26, 2021, 08:00 ET ViaCyte to Present at the Jefferies Virtual Healthcare Conference

ViaCyte, Inc., a clinical-stage regenerative medicine company focused on developing cell therapies that provide a functional cure for patients with...

May 11, 2021, 08:00 ET ViaCyte To Participate In World Medical Innovation Forum Panel On Future Of Cell Therapy For Type 1 Diabetes

Manasi Sinha Jaiman, M.D., M.P.H., Vice President, Clinical Development at ViaCyte, Inc., a clinical-stage regenerative medicine company, will...

Mar 02, 2021, 07:00 ET ViaCyte and Gore Expand Collaboration to Develop Novel Membrane and Device Technologies that Enhance Delivery of Cell Replacement Therapies for Diabetes

ViaCyte, Inc., a clinical stage regenerative medicine company, and W. L. Gore & Associates, Inc. ("Gore"), a leading global materials science company ...

Feb 03, 2021, 08:30 ET ViaCyte Announces Initiation of Phase 2 Study of Encapsulated Cell Therapy for Type 1 Diabetes Patients

ViaCyte, Inc., a clinical-stage regenerative medicine company, today announced that the first type 1 diabetes (T1D) patients have been implanted in a ...

Jan 27, 2021, 16:46 ET ViaCyte Appoints Michael Yang President and CEO and Provides Company Update

ViaCyte, Inc., a clinical-stage regenerative medicine company, today announced the appointment of Michael Yang to President and CEO and as a member...

Aug 13, 2020, 09:00 ET ViaCyte Appoints Dr. Manasi Sinha Jaiman as Vice President, Clinical Development

ViaCyte, Inc., a clinical stage regenerative medicine company, today announced the appointment of Manasi Sinha Jaiman, M.D., M.P.H. as Vice...

Aug 05, 2020, 09:00 ET ViaCyte and Gore Enter Clinical Phase Agreement Based on Novel Membrane Technology for PEC-Encap Product Candidate

ViaCyte, Inc., a clinical stage regenerative medicine company, and W. L. Gore & Associates, Inc. ("Gore"), a leading global materials science company ...

Jul 13, 2020, 09:00 ET ViaCyte Appoints Brittany Bradrick as Chief Financial Officer

ViaCyte, Inc., a clinical stage regenerative medicine company, today announced the appointment of Brittany Bradrick as Chief Financial Officer. Ms....

May 28, 2020, 09:00 ET ViaCyte to Present at the Jefferies Virtual Healthcare Conference

ViaCyte, Inc., a privately held regenerative medicine company, announced today that ViaCyte's President and CEO Paul Laikind, Ph.D. is scheduled to...

May 26, 2020, 09:00 ET ViaCyte Announces $27 Million Financing to Advance Next Generation Cell Therapies for Diabetes

ViaCyte, Inc., a privately held regenerative medicine company, today announced the close of an approximately $27 million private financing, part of...

Jan 08, 2020, 09:00 ET ViaCyte to Present at Biotech Showcase 2020 in San Francisco

ViaCyte, Inc., a privately-held regenerative medicine company, announced today that ViaCyte's President and CEO Paul Laikind, Ph.D. will present at...

Nov 04, 2019, 09:00 ET ViaCyte to Present at ISSCR International Symposium: Stem Cell Biology to New Therapies

ViaCyte, Inc., a privately-held clinical-stage regenerative medicine company, announced an upcoming presentation at From Stem Cell Biology to New...

Oct 03, 2019, 09:00 ET ViaCyte to Present Preliminary PEC-Direct Clinical Data at Cell & Gene Meeting on the Mesa

ViaCyte, Inc., a privately-held regenerative medicine company, will present preliminary data today from the company's PEC-Direct clinical trial at...

Jul 24, 2019, 09:00 ET ViaCyte to Expand Board of Directors with Two New Appointments

ViaCyte, Inc., a privately-held regenerative medicine company, today announced the appointment of Paul J. Hastings and Ian F. Smith to the Company's...

Jun 27, 2019, 09:00 ET ViaCyte Appoints Sandra E. Poole to Board of Directors

ViaCyte, Inc., a privately-held regenerative medicine company, today announced the appointment of Sandra E. Poole to the Company's Board of Directors....

Jan 29, 2019, 09:00 ET ViaCyte Announces New Board Members

ViaCyte, Inc., a privately-held regenerative medicine company, today announced that following the recent $80 million Series D financing, the...

Jan 21, 2019, 09:00 ET Center for Beta Cell Therapy in Diabetes and ViaCyte Announce Start of European Clinical Trial of Human Stem Cell-derived Implants in Type 1 Diabetes Patients

The Center for Beta Cell Therapy in Diabetes, coordinator of an international consortium in translational medicine in diabetes, and ViaCyte, Inc., a...

Jan 04, 2019, 09:00 ET ViaCyte Provides Update on Patent Portfolio in Stem Cell-Derived Cell Replacement Therapies for Type 1 Diabetes and Other Indications

ViaCyte, Inc., a privately-held regenerative medicine company, today announced 165 new patents were issued in 2018. These issued patents provide...

Nov 29, 2018, 00:00 ET ViaCyte Secures $80 Million Financing to Advance Functional Cures for Insulin-Requiring Diabetes

ViaCyte, Inc., a privately-held clinical stage regenerative medicine company, today announced an $80 million Series D financing led by Bain Capital...

Sep 27, 2018, 09:00 ET ViaCyte to Present at Investor, Partnering, and Scientific Conferences in October

ViaCyte, Inc., a privately-held regenerative medicine company, today announced upcoming company presentations at the Cell and Gene Meeting on the...

Sep 25, 2018, 09:00 ET Gore Strengthens Collaborative Relationship with ViaCyte by Investing Additional $10 Million

ViaCyte, Inc., a privately-held regenerative medicine company, and W. L. Gore & Associates, Inc. ("Gore"), a leading global materials science company ...